LXRX
Lexicon Pharmaceuticals Inc
1.80$
-2.9%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -330.9% | 142.1% | -210.7% | -205.2% | -235.1% | 35.3% | -595.8% | -29,200.3% | -63,921.6% | -13,446.6% | -575.2% | -136.2% | |
| 8.4% | 0.6% | 2.5% | 3.8% | 5.8% | 1.1% | 12.2% | 98.0% | 307.2% | 46.0% | 1.7% | 1.2% | |
| 31.0% | 5.3% | 8.9% | 10.5% | 18.5% | 4.4% | 55.3% | 3,549.3% | 8,287.8% | 1,191.0% | 43.4% | 25.1% | |
| 89.1% | 12.6% | 8.1% | -1.2% | 18.5% | 2.5% | 52.4% | 3,565.8% | 8,289.9% | – | – | – | |
| 10.0% | 132.2% | -52.3% | -65.6% | -70.8% | -18.1% | 129.5% | -3,433.2% | 289.2% | 220.8% | 45.8% | -54.0% | |
| 0.4% | 0.7% | 0.3% | 0.3% | 0.2% | 0.0% | 0.4% | 409.7% | 954.0% | 39.0% | 3.3% | 0.0% | |
| -474.4% | -90.0% | 21.9% | 55.9% | 268.3% | -48.4% | 1,586.8% | 708.1% | -51,135.3% | -4,148.1% | -49.5% | 226.9% | |
| 0.0% | 0.0% | 2.4% | 0.0% | – | – | 902.6% | 3,926.2% | – | 8,299.2% | – | – | |
| -3.9% | -0.3% | -0.7% | -1.9% | -1.5% | -0.3% | -4.3% | -897.7% | -621.6% | -68.4% | -5.6% | -1.1% | |
| 360.7% | -1.4% | -2.4% | 159.0% | -3.2% | -0.4% | -902.6% | -3,926.2% | 35,156.8% | 4,149.6% | 0.0% | -96.4% | |
| 1,241.8% | -1.6% | 1.2% | 166.0% | -3.6% | -0.7% | -615.3% | 7,620.5% | 102,308.6% | 15,611.3% | 766.9% | -97.4% | |
| 436.5% | 50.6% | -187.7% | 16.7% | 29.6% | -13.7% | 375.7% | -20,871.8% | -12,748.2% | -1,983.4% | 142.2% | -6.7% | |
| -331.2% | 141.4% | -211.0% | -205.5% | -235.3% | 35.3% | -596.2% | -29,610.1% | -64,875.5% | -13,485.6% | -578.5% | -136.2% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.